Saketh R Guntupalli (Saketh Guntupalli)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Epithelial Mesenchymal Transition

Endoplasmic Reticulum Stress

Top Venues

Molecular cancer therapeutics

Molecular cancer research : MCR

This page only lists publications with an associated author ORCID identifier.

Publications

Lily L Nguyen, Zachary L Watson, Raquel Ortega, Elizabeth R Woodruff, Kimberley R Jordan, Ritsuko Iwanaga, Tomomi M Yamamoto, Courtney A Bailey, Francis To, Abigail D Jeong, Saketh R Guntupalli, Kian Behbakht, Veronica Gibaja, Nausica Arnoult, Alexis Cocozaki, Edward Boyi Chuong, Benjamin G Bitler
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Molecular cancer therapeutics (2024)
Saketh R Guntupalli
Practical implications of the ADNEX risk prediction model for diagnosis of ovarian cancer. BMJ medicine 3 (1) (2024)
Saketh R Guntupalli
Practical implications of the ADNEX risk prediction model for diagnosis of ovarian cancer. BMJ medicine 3 (1) (2024)
Lily L Nguyen, Zachary L Watson, Raquel Ortega, Elizabeth R Woodruff, Kimberley R Jordan, Ritsuko Iwanaga, Tomomi M Yamamoto, Courtney A Bailey, Francis To, Abigail D Jeong, Saketh R Guntupalli, Kian Behbakht, Veronica Gibaja, Nausica Arnoult, Alexis Cocozaki, Edward Boyi Chuong, Benjamin G Bitler
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Molecular cancer therapeutics (2024)
Lily L Nguyen, Zachary L Watson, Raquel Ortega, Elizabeth R Woodruff, Kimberley R Jordan, Ritsuko Iwanaga, Tomomi M Yamamoto, Courtney A Bailey, Francis To, Abigail D Jeong, Saketh R Guntupalli, Kian Behbakht, Veronica Gibaja, Nausica Arnoult, Alexis Cocozaki, Edward Boyi Chuong, Benjamin G Bitler
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. Molecular cancer therapeutics (2024)
Lily L Nguyen, Zachary L Watson, Raquel Ortega, Elizabeth R Woodruff, Kimberley R Jordan, Ritsuko Iwanaga, Tomomi M Yamamoto, Courtney A Bailey, Francis To, Shujian Lin, Fabian R Villagomez, Abigail D Jeong, Saketh R Guntupalli, Kian Behbakht, Veronica Gibaja, Nausica Arnoult, Edward Boyi Chuong, Benjamin G Bitler
EHMT1/2 inhibition promotes regression of therapy-resistant ovarian cancer tumors in a CD8 T cell-dependent manner. Molecular cancer research : MCR (2024)